The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

In fact, the price of such vouchers has been climbing steadily in recent months, according to public disclosures surrounding ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded ...

Unlike VantAI, Amneal has kept its name, focusing its changes instead on its visual identity. The company, which sells ...

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

To promote its newly launched nonhormonal menopause drug, Bayer is linking Lynkuet with a familiar face. The Big Pharma has recruited Gabrielle Union-Wade to serve as a celebrity endorser for the ...

After a whirlwind of conference news Monday, we're doing it all over again with Day 2 of the J.P. Morgan Healthcare ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

Danish dermatology specialist Leo Pharma and its CEO Christophe Bourdon came to San Francisco to attend the J.P. Morgan ...

Less than four months after rejecting Sentynl Therapeutics and Cyprium Therapeutics’ treatment for Menkes disease, the FDA ...